Insulet (NASDAQ:PODD) Hits New 12-Month High at $171.97

Insulet Co. (NASDAQ:PODD)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $171.97 and last traded at $168.96, with a volume of 42471 shares traded. The stock had previously closed at $164.87.

A number of equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Insulet in a research report on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 target price on the stock. Jefferies Financial Group lifted their target price on shares of Insulet from $105.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Monday, October 14th. Leerink Swann reiterated an “outperform” rating and issued a $185.00 target price (up previously from $160.00) on shares of Insulet in a research report on Tuesday, September 24th. Finally, Canaccord Genuity cut shares of Insulet from a “buy” rating to a “hold” rating and boosted their price objective for the company from $135.00 to $145.00 in a research report on Friday, October 18th. Ten analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $151.71.

The business’s 50-day simple moving average is $154.39 and its 200-day simple moving average is $130.33. The stock has a market cap of $8.73 billion, a PE ratio of 3,391.20 and a beta of 0.96. The company has a quick ratio of 3.91, a current ratio of 4.72 and a debt-to-equity ratio of 2.43.

Insulet (NASDAQ:PODD) last announced its earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 9.46%. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.03 EPS. As a group, equities research analysts anticipate that Insulet Co. will post 0.23 earnings per share for the current fiscal year.

In other news, CEO Shacey Petrovic sold 689 shares of Insulet stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $145.69, for a total transaction of $100,380.41. Following the sale, the chief executive officer now owns 94,510 shares of the company’s stock, valued at approximately $13,769,161.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.12, for a total transaction of $606,836.36. Following the sale, the senior vice president now directly owns 22,626 shares in the company, valued at approximately $3,306,111.12. The disclosure for this sale can be found here. Insiders have sold a total of 5,491 shares of company stock worth $806,124 in the last ninety days. Insiders own 3.50% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Advisors Preferred LLC bought a new stake in Insulet during the second quarter worth about $38,000. Harvest Fund Management Co. Ltd bought a new stake in Insulet during the second quarter worth about $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. bought a new stake in Insulet during the second quarter worth about $97,000. Steward Partners Investment Advisory LLC bought a new stake in Insulet during the second quarter worth about $119,000. Finally, Cerebellum GP LLC bought a new stake in Insulet during the third quarter worth about $122,000.

Insulet Company Profile (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

See Also: Put Option

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.